Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
VX1 Stock Chart & Stats
€352.35
€4.45(1.12%)
At close: 4:00 PM EST
€352.35
€4.45(1.12%)
Day’s Range― - ―
52-Week Range€312.65 - €489.20
Previous CloseN/A
Volume2.00
Average Volume (3M)121.00
Market Cap
$91.69B
Enterprise Value€96.43B
Total Cash (Recent Filing)$6.29B
Total Debt (Recent Filing)$1.83B
Price to Earnings (P/E)28.3
Beta0.23
Next Earnings
Feb 04, 2026EPS Estimate
4.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.15
Shares Outstanding253,718,830
10 Day Avg. Volume119
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)6.32
Price to Sales (P/S)9.41
P/FCF Ratio-131.21
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue8.23
Enterprise Value/Gross Profit9.53
Enterprise Value/Ebitda20.93
Forecast
1Y Price Target
$423.58Price Target Upside20.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsVertex reported 3Q25 results with revenue of $3.08B, up 11% y/y, above consensus of $3.06B, and non-GAAP EPS of $4.80 above consensus of $4.58.
Financial PerformanceVertex ended the quarter with $6.3B in cash and marketable securities and no debt.
Pipeline DevelopmentPovetacicept's dual BAFF/APRIL blockade provides true disease-modifying potential, not just symptomatic relief.
Bears Say
Market PerformanceBoth Alyftrek and Journavx missed consensus expectations, indicating challenges in their market performance.
Operating ExpensesOperating expenses were higher than expected in 3Q25 at $1.5B vs. estimate of $1.3B.
Valuation ConcernsAt a premium valuation — Vertex shares currently trade at a P/E multiple of 23.6x 2026E consensus EPS vs. the mega-cap BioPharma peer average of 17.1x — and unclear growth drivers post-CF, a Hold rating is maintained.
Vertex Pharmaceuticals News
VX1 FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was €312.65 and its highest was €489.20 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $91.69B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Feb 04, 2026 which is in 88 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported €4.149 earnings per share for the quarter, beating the consensus estimate of €3.953 by €0.196.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.42.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 253,718,830 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of €4.149 in its last earnings report, beating expectations of €3.953. Following the earnings report the stock price went down -0.041%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:VX1
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$423.58 (20.22% Upside)
$423.58 (20.22% Upside)
Blogger Sentiment
Bullish
DE:VX1 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.67%
12-Months-Change
Fundamentals
Return on Equity
22.31%
Trailing 12-Months
Asset Growth
11.79%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VX1 Company Deck
VX1 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, significant revenue growth across multiple products, and promising pipeline advancements, particularly in the renal and CF segments. However, challenges remain with high gross to net impacts and some regulatory and development delays.View all DE:VX1 earnings summariesVX1 Revenue Breakdown
92.91% TRIKAFTA/KAFTRIO
7.09% Other product revenues
VX1 Stock 12 Month Forecast
Average Price Target
€423.58
▲(20.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---